Psilocybin vs Ketamine-Assisted Psychotherapy and Cardiometabolic Outcomes
This clinical trial aims to compare the effects of psilocybin-assisted psychotherapy (PAP) and ketamine-assisted psychotherapy (KAP) on cardiometabolic health. The study will assess changes in biomarkers like blood pressure, cholesterol, and insulin resistance in participants with treatment-resistant depression. By comparing the two interventions, researchers hope to gain insights into their potential impact on physical health and identify the most effective treatment for improving both mental and physical well-being.
Environmental Drivers of Coronary Heart Disease
The purpose of this research study is to understand the relationship of environmental variables such as smoking, drinking, financial stress, and marital satisfaction on the development of heart disease.
GenePHIT Study
The GenePHIT study is a double-blind, randomized, placebo-controlled trial evaluating a single intracoronary dose of AB-1002 for adults with non-ischemic cardiomyopathy and NYHA Class III heart failure.
Learn more here: